Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/26/2026

1. ACCV
2. GMAB
3. IVBIY
4. IIB:IN
5. AZN
6. DRRD:IN
7. SMMT
8. RDY
9. CART
10. CLYM

Go back to Mirum Pharmaceuticals Reports Third Quarter 2024 Financial Results and Provides Business Update

Mirum Pharamceuticals (MIRM) PT Raised to $70 at Stifel

November 12, 2024 12:51 PM EST

Stifel analyst Dae Gon Ha raised the price target on Mirum Pharamceuticals (NASDAQ: MIRM) to $70.00 (from $66.00) while maintaining a Buy rating.

The analyst comments "Commercial progress (Livmarli, Chenodal, Cholbam) is on a positive trajectory as implied by $90.3M in product revenue with guidance... More